Results · Apr-Jun 2026
Kabra Drugs Q1 FY27 results
Sales grew 546% to ₹46.2 crore from ₹7.2 crore in Apr-Jun 2025.
Operating profit was ₹2.8 crore, an operating margin of 6.0% (up 13.2 points from a year ago).
Net profit turned positive: ₹2.1 crore against a loss of ₹0.5 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +31%, net profit +100%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 46.2 | 7.2 | +546% |
| Operating profit (EBITDA) | 2.8 | -0.5 | n/m |
| Operating margin | 6.0% | −7.2% | +13.2 pts |
| Net profit | 2.1 | -0.5 | turns positive |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.